Breaking Down SG&A Expenses: Pharming Group N.V. vs Veracyte, Inc.

SG&A Expenses: Pharming vs Veracyte - A Decade of Growth

__timestampPharming Group N.V.Veracyte, Inc.
Wednesday, January 1, 2014404202540786000
Thursday, January 1, 2015527955747876000
Friday, January 1, 2016807391352035000
Sunday, January 1, 20174486407355348000
Monday, January 1, 20185348890465276000
Tuesday, January 1, 20196589636182720000
Wednesday, January 1, 20206996826789118000
Friday, January 1, 202192047281181193000
Saturday, January 1, 2022131819000174078000
Sunday, January 1, 202387501000184232000
Loading chart...

Unveiling the hidden dimensions of data

A Comparative Analysis of SG&A Expenses: Pharming Group N.V. vs Veracyte, Inc.

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding the financial dynamics of companies is crucial. Over the past decade, from 2014 to 2023, Pharming Group N.V. and Veracyte, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses.

Pharming Group N.V. started with a modest SG&A expense of approximately $4 million in 2014, which surged to a peak of around $132 million in 2022, marking an impressive increase of over 3,000%. In contrast, Veracyte, Inc. began with $41 million in 2014 and reached $184 million by 2023, reflecting a steady growth of about 350%.

This comparison highlights the strategic financial management and growth trajectories of these companies, offering valuable insights for investors and industry analysts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025